This review illustrates how key biomarkers (SMN2 copy number, neurophysiological measurements, NFs and imaging techniques) can offer critical insights into SMA progression and treatment outcomes at different stages of the disease (Fig. 1 and Table 4), highlighting that no single biomarker can be universally applied across all patients. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.